Cobra Biologics Expands Gene Therapy Manufacturing Operations

April 18, 2017

Cobra will increase capacity in response to customer demand for DNA and viral vector production.

Cobra Biologics, an international contract development and manufacturing organization for biologics and pharmaceuticals, will expand operations at its sites in the United Kingdom and Sweden, the company announced on April 18, 2017. Over the next two years Cobra will invest up to £15 million ($19 million) on a phased expansion plan, supporting the company’s R&D expertise in developing rapid and cost-effective viral vector and DNA plasmid production platforms. The initial phase will be in the UK and will extend the company’s viral vector Phase III and commercial manufacturing capabilities to support more customers to rapidly advance their products through clinical trials to in-market supply. The second phase, in Sweden, will double capacity for high quality (HQ) DNA plasmid production and characterization, essential for supporting early clinical phase adeno-associated virus (AAV) and lentivirus manufacture being used by pioneering CAR T-cell therapy companies targeting acute lymphoblastic leukemia and chronic lymphocytic leukemia. The third phase of investment will see the addition of larger clinical and commercial capabilities for GMP DNA production. In total, it is anticipated these investments will create up to 50 new jobs.

Source: Cobra Biologics